Effects of activated carbon N-acetylcysteine sustained-release microcapsule on miRNA of non-alcoholic fatty liver disease in young rats

doi:10.12092/j.issn.1009-2501.2018.03.004

Abstract

Abstract:

AIM: To primarily investigate the protective effect of active carbon N-acetylcysteine sustained-release microcapsules (ACNAC) on non-alcoholic fatty liver disease (NAFLD) in young rats and explore its effect on miRNA and corresponding target genes. METHODS: The models of NAFLD in young rats were produced by high-fat diets; the degree of fatty degeneration in the liver tissue of young rats was observed by HE staining; the miRNA expression spectra of liver tissues was detected by microRNA microarray. The miRNA was verified by fluorescence quantitative PCR. The target gene prediction and validation were performed for target miRNA by fluorescence quantitative PCR and Western blot. RESULTS:miRNA199a-5p and miRNA-378-5p were the key miRNA of NAFLD, Lpl was the target gene of miR199a-5p, and srebp1 and C/EBP-α were the target genes of miR-378-5p. CONCLUSION:ACNAC can up regulate the expression of Lpl and down regulate the expressions of srebp1 and C/EBP-α,which are closely associated with fatty liver, so they may have a protective effect on NAFLD in young rats.

Key words: N-acetylcysteine, non-alcoholic fatty liver disease, miRNA, Lpl, Srebp1, C/EBP-α

CLC Number:

R965.2

ZHOU Hongping, YANG Xingxin, ZHUANG Rangxiao, SHAO Yidan, XI Jianjun, LIAO Li, REN Bailu, WANG Pingping, YU Shuying, SHI Tingting. Effects of activated carbon N-acetylcysteine sustained-release microcapsule on miRNA of non-alcoholic fatty liver disease in young rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 263-270.

References

［1］Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression［J］. Hepatology, 2008, 48: 1810-1820.
［2］Panera N, Gnani D, Crudele A, et al. MicroRNAs as controlled systems and controllers in nonalcoholic fatty liver disease［J］. World J Gastroenterol, 2014, 20(41): 15079-15086.
［3］Blade C, Baselga-Escudero L, Salvad'o MJ, et al. miRNAs, polyphenols, and chronic disease［J］. Mol Nutr Food Res, 2013, 57(1): 58-70.
［4］Peng Y, Yu S, Li H, et al. MicroRNAs: emerging roles in adipogenesis and obesity［J］. Cell Signal, 2014, 26(9): 1888-1896.
［5］Ceccarelli S, Panera N, Gnani D, et al. Dual role of microRNAs in NAFLD［J］. Int J Mol Sci, 2013, 14(4): 8437-8455.
［6］Abente EJ, Subramanian M, Ramachandran V, et al. MicroRNAs in obesity-associated disorders［J］. Arch Biochem Biophys, 2016, 589: 108-119.
［7］Mahgoub A, Steer CJ. MicroRNAs in the evaluation and potential treatment of liver diseases［J］. J Clin Med, 2016, 5(5): 52.
［8］王冲. MicroRNA研究热点的分析［D］. 北京协和医学院硕士学位论文, 2012.5.
［9］Girard M, Jacquemin E, Munnich A, et al. MiR-122, a paradigm for the role of microRNAs in the liver［J］. J Hepatol, 2008,48(4) : 648-656
［10］方红英，庄让笑，席建军，等. 乙酰半胱氨酸活性炭微囊治疗大鼠肝纤维化的实验研究［J］. 中国临床药理学与治疗学，2015，20(9): 976-980.
［11］Zhou HP, Shi TT, Yan J, et al. Effects of activated carbon N-acetylcysteine sustained-release microcapsule on dipeptidyl peptidase IV expression in young rats with non-alcoholic fatty liver disease［J］. Exp Ther Med, 2017, 14: 4737-4744.
［12］中华医学会肝病学会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南（2010 年修订版）［J］. 中华肝脏病杂志, 2010, 18(3): 163-166.
［13］Brunt EM. Pathology of nonalcoholic fatty liver disease［J］. Nat Rev Gastroenterol Hepatol, 2010, 7(4): 195-203.
［14］Nobili V, Svegliati-Baroni G, Alisi A, et al. A 360-degree overview of paediatric NAFLD: recent insights［J］. J Hepatol, 2013, 58(6): 1218-1229.
［15］展玉涛. 儿童非酒精性脂肪性肝病研究进展［J］. 实用肝脏病杂志, 2006, 9(2): 101-103.
［16］韦君, 樊晓明. microRNAs在肝脏中的作用［J］. 世界华人消化杂志, 2012, 20(1): 1-8.
［17］赵文霞, 闫乐, 邵明义, 等. 化痰祛湿活血方对非酒精性脂肪性肝炎大鼠ADPN/AMPK/ACC通路的影响［J］. 临床肝胆病杂志, 2017, 33(5): 932-938.
［18］邵芳, 朱斌, 顾志良. MicroRNA在脂类代谢中的功能研究进展［J］. 生命科学, 2013, 25(7): 676-684.

[1]	MA A'xue, LU Xiaohong, DONG Bo, WANG Dong. Research progress of exosomal miRNA in skin wound healing and regeneration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 919-924.
[2]	WU Shuai, YANG Jun, ZHENG Yun. Dual role of miRNA in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 814-821.
[3]	DING Hao, GAO Zhenhua, ZHENG Yun. Research progress of microRNA in diagnosis and treatment of prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 696-708.
[4]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[5]	ZHANG Liang, LIAO Yongqun, XIA Qinchuan, ZHOU Shitong, LI Xiaoli. Ferroptosis regulatory signaling pathway and its research progress in related diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 227-234.
[6]	ZHANG Jianmin, LENG Yufang, LIU Xin, REN Yixing, SHI Yajing, CHEN Feng. Research progress on the mechanism of miRNA in intestinal ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 332-340.
[7]	LU Chenyu, YANG Jun, LIU Yixi, ZHENG Yun. Function and regulation of miRNAs associated with Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 775-783.
[8]	WU Jiayuan, ZHENG Li, MO Juanfen, GUO Li, CAO Chenxi, BAO Yi. Regulation of N-acetylcysteine on peripheral circulatory and hepatic myeloid-derived suppressor cells in non-alcoholic fatty liver disease mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 989-996.
[9]	BAI Xuemin, ZOU Likao, JIN Zhenmu, JIANG Lijia. Effects of N-acetylcysteine on regulation of EGFR/MAPK signaling pathway in airway mucus hypersecretion in chronic obstructive pulmonary disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1120-1127.
[10]	PAN Xiaoqiu, ZHAI Hongjun, LI Lihui, BAN Yaolin. Study on differential expression of the mi-RNA in the deep second degree burns [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1321-1328.
[11]	MEI Ying, LIU Chaoqi. Advances in research of miRNA regulated tumor-associated gene c-met [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 204-209.
[12]	KONG Xiang, HUA Qiang, MENG Xiangjian, YAO Xinming, WANG Yong, XIA Libin. Clinical implications of circulating miRNA-101 expression level in patients with newly diagnosed type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1406-1409.
[13]	SONG Li-ying, PENG Xiang-dong, WANG Chun-jiang, GUO Ren, LIU Shi-kun. Recent progress in the role of miRNA in hepatic stellate cells activation and the chronic hepatic diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1422-1428.
[14]	GUO Yu, ZHOU Hong-hao, LIU Zhao-qian. MiRNA and interindividual difference in drug response [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 443-448.
[15]	WAN Jing-zhi, YUAN Ding, WANG Ting. Research advances in Sirt1 regulating microRNA [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1430-1435.